U.S. market Closed. Opens in 3 hours

GLYC | GlycoMimetics, Inc. Stock Overview

(Stock Exchange: NASDAQ)
Day's Range 0.3104 - 0.3690
52 Week Range 0.1400 - 3.53
Beta 2.42
Implied Volatility 591.89%
IV Rank 34.67%
Day's Volume 3,458,339
Average Volume 19,794,458
Shares Outstanding 64,483,999
Market Cap 21,279,720
Sector Healthcare
Industry Biotechnology
IPO Date 2014-01-10
Valuation
Profitability
Growth
Health
P/E Ratio -0.53
Forward P/E Ratio -2.09
EPS -0.62
1YR Price Target 5.50
Dividend Yield N/A
Dividend Per Share N/A
Dividend ExDate N/A
Dividend PayDate N/A
Employees 35
Country USA
Website GLYC
GlycoMimetics Inc is a clinical stage biotechnology company. It is focused on the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in which carbohydrate biology plays a key role. Glycomimetics are molecules that mimic the structure of carbohydrates involved in important biological processes. Using expertise in carbohydrate chemistry and knowledge of carbohydrate biology, the company is developing a pipeline of proprietary glycomimetics that may inhibit disease-related functions of carbohydrates, such as the roles it plays in inflammation, cancer, and infection.
GLYC's peers: CDTX, MLYS, FHTX, IVA, DYN, LIFE, TRVI, CUE, ANTX, BCAB, ASMB, SPRO, ACHL, TIL, NLTX
*Chart delayed
Analyzing fundamentals for GLYC we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is desperately bad and Health is very weak. For more detailed analysis please see GLYC Fundamentals page.

Watching at GLYC technicals we can see that long-term trend is bearish, the same as bearish middle-term trend, as well as bearish short-term trend. More technicals details can be found on GLYC Technicals page.
An error has occurred. This application may no longer respond until reloaded. Reload 🗙